CJC-1295 (with DAC) vs CJC-1295 (without DAC) / Mod-GRF 1-29: Complete Comparison Guide

TL;DR — The 90-Second Answer The key distinction between CJC-1295 (with DAC) and CJC-1295 (without DAC) / Mod-GRF 1-29 lies in their half-lives and dosing frequency. CJC-1295 (with DAC) has a 6-8 day half-life due to its Drug Affinity Complex modification, allowing weekly dosing and sustained GH elevation, but carries a higher side effect profile. CJC-1295 (without DAC) / Mod-GRF 1-29 has a 30-minute half-life, requiring multiple daily doses but better mimicking natural pulsatile GH secretion with milder side effects. Choice depends on whether sustained elevation or natural pulsatile release aligns with your protocol goals. Not FDA-approved for human use. For research and educational purposes only. Do not self-administer. Consult a licensed physician before use. This content is not medical advice.

---

At a Glance: Key Differences

---

What Is CJC-1295 (with DAC)?

CJC-1295 (with DAC) is a long-acting synthetic growth hormone-releasing hormone (GHRH) analog engineered with Drug Affinity Complex technology. The DAC modification allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life to 6-8 days. This extended duration means it provides sustained stimulation of GHRH receptors in the pituitary gland, resulting in continuous elevation of growth hormone and IGF-1 levels over days. Researchers and longevity-focused clinics typically use CJC-1295 (with DAC) for sustained GH augmentation in anti-aging and body composition protocols. It requires only 1-2 injections per week, making it convenient for long-term programs. However, the sustained elevation can produce more pronounced side effects than shorter-acting alternatives, and IGF-1 levels require regular monitoring to stay within therapeutic windows.

---

What Is CJC-1295 (without DAC) / Mod-GRF 1-29?

CJC-1295 (without DAC) / Mod-GRF 1-29 is a shorter-acting GHRH analog that preserves the body's natural pulsatile growth hormone secretion pattern. With a 30-minute half-life, it stimulates the pituitary for a brief window before clearing, mimicking the GH pulses that occur naturally throughout the day. This approach respects the body's endogenous feedback mechanisms and avoids the chronic elevation seen with longer-acting compounds. Practitioners typically use CJC-1295 (without DAC) / Mod-GRF 1-29 in protocols requiring 2-3 daily injections, often stacked with GHRP peptides like Ipamorelin for synergistic GH release. The short half-life translates to fewer systemic side effects compared to DAC-modified versions. This peptide appeals to researchers seeking to optimize GH dynamics without the burden of continuous hormonal elevation, particularly in protocols emphasizing metabolic optimization and lean body mass gains.

---

Mechanism of Action: How They Work Differently

Both CJC-1295 (with DAC) and CJC-1295 (without DAC) / Mod-GRF 1-29 are synthetic analogs of the naturally occurring GHRH(1-29) peptide, but their structural modifications produce fundamentally different pharmacokinetic profiles. CJC-1295 (with DAC) incorporates D-amino acid substitutions and a Drug Affinity Complex that binds the peptide to albumin, creating a depot effect that extends its circulating half-life to 6-8 days (PMID: 16352683). This prolonged presence continuously stimulates pituitary GHRH receptors, elevating GH and IGF-1 in a sustained manner rather than pulsatile. In contrast, CJC-1295 (without DAC) / Mod-GRF 1-29 uses selective D-amino acid modifications without the albumin-binding complex, resulting in a 30-minute half-life. This short duration allows the peptide to create acute GH pulses that mimic the body's endogenous secretion pattern, allowing normal feedback suppression between pulses. The mechanistic difference explains their distinct clinical applications: sustained elevation versus dynamic pulsatility.

---

Use Cases: Who Should Choose Which?

CJC-1295 (with DAC) suits researchers pursuing sustained growth hormone elevation for anti-aging protocols, body composition changes, and chronic GH insufficiency models. Its once or twice weekly dosing makes it practical for individuals prioritizing convenience over physiologic mimicry. The sustained GH and IGF-1 elevation may benefit those targeting long-term metabolic shifts and recovery from intense training. However, the continuous elevation carries higher side effect risk and requires diligent IGF-1 monitoring. CJC-1295 (without DAC) / Mod-GRF 1-29 appeals to researchers seeking to preserve natural GH secretion patterns while amplifying endogenous GH pulses. It works well in protocols combining multiple pulsatile GH secretagogues (e.g., GHRP peptides) to create a more physiologic hormone environment. The shorter half-life and lower side effect profile make it suitable for longer protocol cycles. Choice between them depends on whether your research goals favor sustained elevation or pulsatile optimization, and your tolerance for more frequent dosing and monitoring requirements.

---

Dosing & Protocol Notes

CJC-1295 (with DAC) is dosed at 1mg to start, escalating to a maintenance dose of 1-2mg, with a maximum of 2mg per injection. Frequency is 1-2 times weekly via subcutaneous injection to the abdomen or thigh. Timing should be before bed on an empty stomach. Standard cycles run 3-6 months with appropriate post-cycle management. CJC-1295 (without DAC) / Mod-GRF 1-29 begins at 100mcg, scaling to a maintenance range of 100-300mcg, with a ceiling of 300mcg per dose. Dosing frequency is 2-3 times daily via subcutaneous injection, also to the abdomen or thigh. Optimal timing is before meals and at bedtime on an empty stomach; allow at least 20 minutes between injection and food intake for proper absorption. Cycles typically run 8-12 weeks with defined on-off periods. Both require physician supervision to monitor IGF-1 levels and adjust dosing based on individual response and tolerance.

Important: All dosing must be supervised by a licensed physician. Neither CJC-1295 (with DAC) nor CJC-1295 (without DAC) / Mod-GRF 1-29 is FDA-approved for human use. This content is for research and educational purposes only.

---

Can They Be Combined?

Limited clinical data exists on the safety and efficacy of combining CJC-1295 (with DAC) and CJC-1295 (without DAC) / Mod-GRF 1-29 in a single protocol. The sustained mechanism of CJC-1295 (with DAC) and the pulsatile mechanism of CJC-1295 (without DAC) / Mod-GRF 1-29 create opposing GH release profiles, and concurrent use would likely produce unpredictable GH dynamics. Both peptides are commonly stacked with GHRP peptides like Ipamorelin to enhance GH secretion through synergistic receptor pathways. Researchers typically choose one GHRH strategy (sustained vs. pulsatile) rather than combining both. Any protocol combining multiple peptides or hormonal agents requires oversight from a qualified physician.

---

Research Citations

All citations verified against PubMed at time of generation.

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 — PMID 16352683

*Foundational pharmacokinetic study establishing CJC-1295 (with DAC) extended half-life and sustained GH stimulation mechanism that forms the basis of this comparison.*

---

Frequently Asked Questions

Which is more effective for sustained growth hormone elevation?

CJC-1295 (with DAC) is designed specifically for sustained GH elevation due to its 6-8 day half-life and DAC modification that binds to albumin. It continuously stimulates GHRH receptors in the pituitary, keeping GH and IGF-1 levels consistently elevated. CJC-1295 (without DAC) / Mod-GRF 1-29, with its 30-minute half-life, cannot provide sustained elevation and instead creates acute GH pulses. For protocols prioritizing continuous GH elevation, CJC-1295 (with DAC) is the appropriate choice.

What is the key difference in how they work?

CJC-1295 (with DAC) binds to albumin via its Drug Affinity Complex, circulating for 6-8 days and producing continuous GHRH receptor stimulation and sustained GH elevation. CJC-1295 (without DAC) / Mod-GRF 1-29 lacks the albumin-binding modification, remaining active for only 30 minutes before clearing, which creates brief pulsatile GH releases that mimic the body's natural secretion pattern rather than chronic elevation.

Can CJC-1295 (with DAC) and CJC-1295 (without DAC) / Mod-GRF 1-29 be taken together?

Limited clinical data exists on combining these two peptides. CJC-1295 (with DAC) and CJC-1295 (without DAC) / Mod-GRF 1-29 create opposing GH release profiles—one sustained, one pulsatile—and concurrent use would likely produce unpredictable GH dynamics. Researchers typically select one GHRH strategy rather than combining both. Any multi-peptide protocol requires physician oversight to monitor biological markers.

Which has a better safety profile?

CJC-1295 (without DAC) / Mod-GRF 1-29 generally presents a milder side effect profile. Its short 30-minute half-life means it produces minimal sustained systemic effects; common side effects are limited to mild injection site reactions, temporary flushing, and occasional headache. CJC-1295 (with DAC), due to its sustained elevation and longer circulating time, can produce more pronounced side effects including injection site reactions, fatigue, flushing, water retention, and vivid dreams. Monitoring and physician supervision are essential for both.

How does Alethea Health help track CJC-1295 (with DAC) or CJC-1295 (without DAC) / Mod-GRF 1-29 protocols?

Alethea Health provides a peptide protocol tracker designed to log doses, track side effects, monitor injection schedules, and record biological markers like IGF-1 levels across your entire protocol cycle. Whether you're managing a CJC-1295 (with DAC) regimen requiring weekly dosing or a CJC-1295 (without DAC) / Mod-GRF 1-29 protocol with 2-3 daily injections, Alethea Health's tracking system ensures protocol adherence, helps identify patterns in your response, and facilitates data sharing with your supervising physician for informed dosing adjustments.

---

Track Your Results with Alethea Health

Whether you're researching CJC-1295 (with DAC), CJC-1295 (without DAC) / Mod-GRF 1-29, or both, tracking your protocol and biomarkers is the fastest path to understanding what works for your biology.

Start tracking your peptide protocol →

Alethea Health lets you log doses, side effects, and lab results — then surfaces patterns so you and your provider can make data-driven decisions.

---

All peptide guides · Free dose calculator

Educational reference only — not medical advice. Work with a qualified clinician.